Melanoma

- IRB#11848: Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
- IRB#16162: A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Uveal Melanoma Patients
- IRB#16848: A Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
- IRB#15661: A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB#16125: A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides
- IRB#16198: A Phase 1 Dose Escalation Trial of Tumor Injections of IMCgp100 + Durvalumab or Tremelimumab or Durvalumab + Tremelimumab Compared to IMCgp100 Alone
- IRB#16225: A Phase 1b/II Open-label Study of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

Adjuvant Therapies

- Stages 2B, 2C, or 3
- Stages 3 or 4 resectable

Non-Mutation Specific

- Stages 3 or 4, unresectable

Mutation Specific

- BRAF V600 Mutation

Please refer to Phase I studies for more clinical trial opportunities

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold